Outlook Therapeutics, Inc.

NASDAQ:OTLK

Biotechnology

Healthcare
$0.41 -5.76%

-$0.10 today

Market cap
$99.30M
Beta
0.98
P/E (TTM)
-2.1
EPS (TTM)
-$0.74
52W Low $0.16High $3.39

Volume 4.42M

Average 17.46M

OTLK Gross Profit

Revenue minus cost of revenue: what remains to cover operating expenses after paying for what was sold.

Outlook Therapeutics, Inc.NASDAQ: OTLK

Gross Profit · Q2 FY2026 · quarter ended Mar 2026

Gross profit turns negative

Q2 FY2026 gross profit was -$21.89K, compared with $0 a year earlier. Trailing-twelve-month gross profit was -$1.2M.

Context

  • Gross profit amounted to 46.5% of revenue in FY2025.
  • Gross profit increased in 2 of the last 3 fiscal years.
  • FY2025 was the highest annual figure in the 4 fiscal years shown.

What to watch

Whether quarterly gross profit holds near -$21.89K or moves back toward the trailing-twelve-month quarterly average of -$300.54K.

Sources:Income StatementText generated from reported figures; not investment advice.

Latest quarterMar 2026
-$21.89K+98.2% QoQ
Last fiscal yearSep 2025
$657.21K+677.2% YoY
LTMMar 2026
-$1.2M-4457.3% YoY
Gross Profit past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter———
1 year+677.2%——
3-year CAGR———
5-year CAGR——
10-year CAGR——

Gross Profit history

USD · from the income statement

Latest · FY2025
657.21K USD
Year-over-year change
+677.2%

Gross Profit vs competitors

How OTLK compares with its peers on the latest reported figures

  • OTLK's LTM Mar 2026 gross profit of -$1.2M is the 8th highest of the 9 companies compared; the peer median is $425.5K.
  • Its year-over-year change of -4457.3% is the 8th highest of 9, against a peer median of +104.3%.
  • Gross profit amounts to 360.9% of revenue for OTLK, versus a peer median of 86.8%.
OTLK Competitors Peer median
Gross Profit for OTLK and competitors
Company Period LTM YoY 3-year CAGR% of revenue
CUECue Biopharma, Inc.LTM Mar 2026$32.65M +308.6%+180.5%99.8%
HOWLWerewolf Therapeutics, Inc.LTM Jun 2026$18.15M +2281.5%—86.4%
COEPCoeptis Therapeutics, Inc.LTM Mar 2026$1.23M +6860.8%—87.2%
NRXPNRx Pharmaceuticals, Inc.LTM Mar 2026$851K +21375.0%—37.1%
SPRBSpruce Biosciences, Inc.LTM Mar 2026$0 -100.0%——
EQEquillium, Inc.LTM Mar 2026-$79K -100.3%——
OSTXOS Therapies IncorporatedLTM Mar 2026-$362.39K -17280.8%——
OTLKOutlook Therapeutics, Inc.LTM Mar 2026-$1.2M -4457.3%—360.9%
IPSCCentury Therapeutics, Inc.LTM Mar 2026-$29.86M -126.0%+164.4%—
Peer median (excluding OTLK) $425.5K+104.3%+172.4%86.8%

Competitors are the stored peer set for OTLK. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

USD
Metric
FY2021
Sep 2021
FY2022
Sep 2022
FY2023
Sep 2023
FY2024
Sep 2024
FY2025
Sep 2025
Revenue00001.41M
Cost of Revenue262.14K204.69K44.19K113.86K756.33K
Gross Profit(262.14K)(204.69K)(44.19K)(113.86K)657.21K
Gross Margin————46.5%
Research & Development38.96M42.33M26.45M41.76M27.18T
Selling, General & Admin12.77M20.74M26.67M29.94M39.94M
Operating Expenses51.73M62.87M53.13M71.7M67.72M
Depreciation & Amortization262.14K204.69K44.19K113.86K117.05K
EBITDA(51.51M)(64.36M)(57.38M)(72.09M)(63.58M)
EBITDA Margin————-4497.7%
Operating Income(51.73M)(63.07M)(53.13M)(71.7M)(67.06M)
Operating Margin————-4744.3%
Interest Income000906.15K89.74K
Interest Expense936.13K1.49M1.56M3.16M283.13K
Other Income / Expenses(1.43M)(2.98M)(5.85M)(3.66M)3.08M
Income Before Tax(53.16M)(66.05M)(58.98M)(75.36M)(63.98M)
Pre-Tax Margin————-4526.0%
Income Tax Expense2K2.8K2.8K2.8K(1.55M)
Net Income(53.16M)(66.05M)(58.98M)(75.37M)(62.42M)
Net Margin————-4416.2%
EPS (Basic)(6.96)(6.23)(4.72)(4.06)(1.79)
EPS (Diluted)(6.96)(6.23)(4.72)(4.06)(1.79)
Weighted Avg Shares7.63M10.6M12.51M18.55M34.8M
Weighted Avg Shares (Diluted)7.63M10.6M12.51M18.55M25.48M

Outlook Therapeutics, Inc.

NASDAQ:OTLK

Intrinsic Alpha fair value

Locked

Current Price

$0.41

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.